JP2023520759A5 - - Google Patents

Info

Publication number
JP2023520759A5
JP2023520759A5 JP2022557736A JP2022557736A JP2023520759A5 JP 2023520759 A5 JP2023520759 A5 JP 2023520759A5 JP 2022557736 A JP2022557736 A JP 2022557736A JP 2022557736 A JP2022557736 A JP 2022557736A JP 2023520759 A5 JP2023520759 A5 JP 2023520759A5
Authority
JP
Japan
Prior art keywords
dione
piperidine
oxo
dihydro
isoindole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022557736A
Other languages
English (en)
Japanese (ja)
Other versions
JP7698658B2 (ja
JP2023520759A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023382 external-priority patent/WO2021194914A1/en
Publication of JP2023520759A publication Critical patent/JP2023520759A/ja
Publication of JP2023520759A5 publication Critical patent/JP2023520759A5/ja
Application granted granted Critical
Publication of JP7698658B2 publication Critical patent/JP7698658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022557736A 2020-03-23 2021-03-22 がん治療のための置換オキソイソインドリン化合物 Active JP7698658B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993144P 2020-03-23 2020-03-23
US62/993,144 2020-03-23
PCT/US2021/023382 WO2021194914A1 (en) 2020-03-23 2021-03-22 Substituted oxoisoindoline compounds for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2023520759A JP2023520759A (ja) 2023-05-19
JP2023520759A5 true JP2023520759A5 (cg-RX-API-DMAC7.html) 2024-04-02
JP7698658B2 JP7698658B2 (ja) 2025-06-25

Family

ID=75478287

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557736A Active JP7698658B2 (ja) 2020-03-23 2021-03-22 がん治療のための置換オキソイソインドリン化合物

Country Status (14)

Country Link
US (1) US12570671B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126843B1 (cg-RX-API-DMAC7.html)
JP (1) JP7698658B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220158256A (cg-RX-API-DMAC7.html)
CN (1) CN115605466B (cg-RX-API-DMAC7.html)
AR (1) AR121600A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021241458A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018706A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172626A1 (cg-RX-API-DMAC7.html)
ES (1) ES3065771T3 (cg-RX-API-DMAC7.html)
IL (1) IL296676B2 (cg-RX-API-DMAC7.html)
MX (1) MX428243B (cg-RX-API-DMAC7.html)
TW (1) TW202140441A (cg-RX-API-DMAC7.html)
WO (1) WO2021194914A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188549A1 (en) * 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7863100B2 (ja) * 2020-10-14 2026-05-20 シーフォー セラピューティクス, インコーポレイテッド Ikzf2又はikzf4を分解する三環式リガンド
PE20231941A1 (es) * 2021-04-06 2023-12-05 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物
CN118488948A (zh) * 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
US20240124412A1 (en) * 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN116640122A (zh) * 2022-02-16 2023-08-25 苏州国匡医药科技有限公司 Ikzf2降解剂及包含其的药物组合物和用途
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
US20250214991A1 (en) * 2022-03-25 2025-07-03 Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs Bicyclic heteroaryl-containing compounds as ikzf2 degraders
CN114702440B (zh) * 2022-04-26 2024-06-18 永农生物科学有限公司 一种氨氯吡啶酸的制备方法及制备的氨氯吡啶酸
WO2024096753A1 (en) * 2022-11-02 2024-05-10 Captor Therapeutics S.A. Nek7 degraders and methods of use thereof
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69740140D1 (de) 1996-07-24 2011-04-14 Celgene Corp Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
DE60231989D1 (de) 2001-08-06 2009-05-28 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CA2663057C (en) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP5561577B2 (ja) 2009-07-01 2014-07-30 国立大学法人 名古屋工業大学 光学活性3’−フルオロサリドマイド誘導体の製造方法
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2015107196A1 (en) 2014-01-20 2015-07-23 Institut Curie Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
CN104230787B (zh) 2014-08-20 2016-08-24 华东师范大学 N-(1,3-二氧代异吲哚啉)芳酰胺类化合物及其制备方法和应用
AU2016266942B2 (en) 2015-05-22 2018-10-18 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
CA2988414C (en) 2015-06-04 2023-09-26 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
US10830762B2 (en) 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
CN109153644B (zh) 2016-03-16 2022-10-21 H·李·莫菲特癌症中心研究有限公司 用以增强效应t细胞功能的针对cereblon的小分子
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
US10865205B2 (en) 2016-04-22 2020-12-15 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CA3036834A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
IL266842B (en) * 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
CN110753693A (zh) 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
IL325835A (en) 2016-12-23 2026-03-01 Univ Yale Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
SG11202003415XA (en) * 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
JP2021512153A (ja) 2018-01-26 2021-05-13 イエール ユニバーシティ タンパク質分解のイミド系モジュレーターおよび使用方法
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
US11191769B2 (en) 2018-06-13 2021-12-07 Biotheryx, Inc. Fused thiophene compounds
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
BR122022012697B1 (pt) * 2018-07-10 2023-04-04 Novartis Ag Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
JP2022507267A (ja) 2018-11-13 2022-01-18 バイオセリックス, インコーポレイテッド 置換イソインドリノン
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7629459B2 (ja) * 2019-11-19 2025-02-13 ブリストル-マイヤーズ スクイブ カンパニー Heliosタンパク質の阻害剤として有用な化合物

Similar Documents

Publication Publication Date Title
JP7434186B2 (ja) 自己免疫疾患の処置のための新規のヘテロアリールヘテロシクリル化合物
KR101491865B1 (ko) N-에틸퀴놀론 및 n-에틸아자퀴놀론의 유도체 및 유사체
AU2018388406B2 (en) Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN113164459B (zh) 单酰基甘油脂肪酶调节剂
ES2989387T3 (es) Pequeñas moléculas inhibidoras de la quinasa inductora de nf-kb
TW201940167A (zh) Shp2抑制劑及其用途
KR101590236B1 (ko) 카세인 키나제 억제제로서의 신규한 융합된 피리딘 화합물
JP2021518395A5 (cg-RX-API-DMAC7.html)
JP2020510092A5 (cg-RX-API-DMAC7.html)
WO2015025025A1 (en) Alkynyl alcohols and methods of use
WO2021194914A1 (en) Substituted oxoisoindoline compounds for the treatment of cancer
WO2024193683A1 (en) Bicyclic derivatives, compositions and uses thereof
KR20080064173A (ko) 항균제로서 유용한 페리 축합 트리시클릭 화합물
JP7296992B2 (ja) 細菌感染症の処置および予防のための新規オキソキノリジン化合物
AU2024333590A1 (en) Compounds and compositions as cbp/p300 degraders and uses thereof
KR20230069963A (ko) 카제인 키나아제 1 델타 조절제
JP2010524890A (ja) 化合物
AU2023267747A1 (en) Tetrahydropyrido[3,4-d]pyrimidines compounds as hpk1 inhibitors
TW202246261A (zh) 作為抗癌劑的化合物
EA048566B1 (ru) Модуляторы моноацилглицерин-липазы
HK40039183A (en) Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease